Dr. Martens plc (LON:DOCS)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 587.53M +10.8% |
| Revenue (ttm) | 785.00M -2.6% |
| Net Income | 15.30M -48.0% |
| EPS | 0.02 -49.2% |
| Shares Out | 967.93M |
| PE Ratio | 39.26 |
| Forward PE | 13.37 |
| Dividend | 0.03 (4.20%) |
| Ex-Dividend Date | Mar 5, 2026 |
| Volume | 572,156 |
| Average Volume | 904,667 |
| Open | 64.40 |
| Previous Close | 64.40 |
| Day's Range | 61.10 - 65.13 |
| 52-Week Range | 53.05 - 100.87 |
| Beta | 0.22 |
| RSI | 51.24 |
| Earnings Date | May 19, 2026 |
About Dr. Martens
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom. [Read more]
Financial Performance
In fiscal year 2025, Dr. Martens's revenue was 787.60 million, a decrease of -10.20% compared to the previous year's 877.10 million. Earnings were 4.50 million, a decrease of -93.50%.
Financial StatementsNews
Dr. Martens Earnings Call Transcript: Q3 2026
Q3 saw accelerated growth in the Americas, strong wholesale gains across all regions, and robust performance in shoes, while EMEA retail lagged due to a tough consumer environment. Inventory and cost controls remain strong, and early U.S. price increases show no negative impact.
Dr. Martens Revenue Drops on Europe, Middle East and Africa Weakness
Chief Executive Ije Nwokorie said the EMEA market continued to be challenging, and that the company had taken a more disciplined promotional stance there.
Dr. Martens Earnings Call Transcript: H1 2026
Revenue and profit improved year-on-year, driven by higher full-price sales, cost control, and growth in the Americas and APAC. Strategic execution is on track, with new product launches, expanded partnerships, and technology investments supporting future growth.
Dr. Martens Transcript: Strategy Update
A new consumer-first strategy aims to drive sustainable, profitable growth by broadening product offerings, optimizing market-specific distribution, and leveraging brand strengths. Financial discipline, operational improvements, and technology investments support mid to high teens EBIT margin targets over the medium term.
Dr Martens forecasts return to profit growth, shares jump
British bootmaker Dr Martens forecast a return to profit growth in the current financial year on Thursday, backed by its new CEO's plan to put more emphasis on shoes, sandals, and bags, as well as the...
Dr. Martens Earnings Call Transcript: H2 2025
Stabilization achieved with all key objectives met, including Americas DTC growth, cost reduction, and significant inventory and debt reduction. Revenue and profit declined YoY but were in line with guidance, and the business is positioned for future growth.
Dr. Martens Selects Amperity to Transform Customer Data Strategy
LONDON--(BUSINESS WIRE)-- #AdTech--Amperity, an AI-powered customer data cloud, today announced Dr. Martens, an iconic British brand, has selected its platform to support its global data and marketing...
Dr. Martens Earnings Call Transcript: Q3 2025
Q3 results met expectations with USA DTC up 4% and APAC strong, while EMEA was flat due to less discounting. Guidance is unchanged, inventory is down, and cost savings are on track. Product-led marketing and new products are driving positive momentum.
Dr. Martens Shares Soar Despite H1 Loss
Shares of the UK-based Dr. Martens PLC ($GB:DOCS) soared 13% as of writing, despite the company reporting a loss in its H1 results for FY25. The footwear company, known for…
Dr Martens' shares jump 15% on new CEO's start date despite drop in first half sales
Dr Martens said its new CEO Ije Nwokorie will take over from incumbent Kenny Wilson on Jan. 6 2025, in a shakeup investors hope could boost the struggling boot maker
Dr. Martens Earnings Call Transcript: H1 2025
First half results met expectations with revenue down 16% and gross margin stable year-on-year. Cost savings, inventory reduction, and refinancing strengthened the balance sheet, while product-focused marketing and DTC improvements set the stage for H2 growth.
Dr Martens sees strong US holiday sales, cuts inventory and debt
Dr Martens said on Thursday that the autumn-winter festive season had got off to an encouraging start and investors welcomed a reduction in net debt as the bootmaker tries to turn its performance arou...
Dr. Martens shares plunge to record lows on discount bulk sale via Goldman Sachs
Dr. Martens' investors sold 70 million shares in the bootmaker at a price of 57.85 pence per share, in what marks a 10% discount on its closing share price on Thursday
Dr. Martens Earnings Call Transcript: H2 2024
Dr Martens will cut up to £25m in costs to counter weak US sales
British footwear brand does not rule out job losses, while profits fall by 43% to £97m
Dr. Martens Stock Plummets on Downbeat US Outlook
U.K.-listed Dr. Martens PLC issued a downbeat outlook for its U.S. sales on Tuesday, noting that it expects wholesale revenue in the country to be down by double digits for its fiscal 2025 year, and s...
Dr. Martens' profit warning highlights U.S. consumer-confidence challenge
Dr. Martens' profit warning sent shares of the iconic shoe brand tumbling Tuesday and spotlighted consumer-spending challenges on both sides of the Atlantic.
Dr. Martens Shares Tumble as Bootmaker Warns of Tough Year
Dr. Martens shares plummeted after the iconic British footwear and clothing brand said Chief Executive Officer Kenny Wilson plans to step down and warned of a challenging year ahead.
Dr. Martens shares lose a third of their value on U.S. warning
Shares of iconic shoe brand Dr. Martens fell as much as 32% on Tuesday with the company's U.S. business going so badly it needs to extend paying for additional storage space as it announced its chief ...
Dr. Martens shares plunge 30% to all-time low, trading briefly halted on weak outlook
Shares of Dr. Martens plunged to a record low in early deals after the shoemaker flagged a challenging 2025 outlook.
Bootmaker Dr Martens names new CEO, flags tough year on weak demand
British bootmaker Dr Martens named its chief brand officer Ije Nwokorie as its next CEO on Tuesday, saying Kenny Wilson had decided this year would be his final year as top boss.
Exclusive: Marathon Partners pushes Dr. Martens for strategic review, possible sale
Investment firm Marathon Partners Equity Management wants British boot maker Dr. Martens to hire bankers and begin an immediate strategic review that could lead to a sale of the company, according to ...
Dr Martens' revenue plummets by a fifth as US sales plunge
Bootmaker says global sales fell by 18%, with cash-strapped consumers refusing to splash out at Christmas
Dr. Martens Transcript: Trading Update
Bootmaker Dr Martens hit by weak December as US sales slide
Britain's Dr Martens said its visibility over wholesale orders "remains weak" as the bootmaker posted a drop in third-quarter revenue on Thursday following several profit warnings and a disappointing ...